Regulus Therapeutics Inc (NASDAQ:RGLS) – Investment analysts at Wedbush issued their FY2022 EPS estimates for Regulus Therapeutics in a research note issued on Thursday. Wedbush analyst L. Moussatos expects that the biopharmaceutical company will post earnings of $0.47 per share for the year. Wedbush currently has a “Outperform” rating and a $4.00 target price on the stock.
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Wednesday, January 24th. Leerink Swann began coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $2.00 price objective for the company. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $2.50.
Institutional investors have recently added to or reduced their stakes in the company. NEA Management Company LLC bought a new position in shares of Regulus Therapeutics during the 3rd quarter valued at approximately $13,737,000. Victory Capital Management Inc. bought a new position in shares of Regulus Therapeutics during the 3rd quarter valued at approximately $347,000. Goldman Sachs Group Inc. grew its position in shares of Regulus Therapeutics by 189.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 240,890 shares during the period. Candriam Luxembourg S.C.A. bought a new position in shares of Regulus Therapeutics during the 3rd quarter valued at approximately $750,000. Finally, South Dakota Investment Council grew its position in shares of Regulus Therapeutics by 37.1% during the 3rd quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock valued at $2,275,000 after acquiring an additional 492,969 shares during the period. 59.32% of the stock is owned by hedge funds and other institutional investors.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.